Effective phages as green antimicrobial agents against antibiotic-resistant hospital Escherichia coli

Jundishapur Journal of Microbiology

Volumn 8, Issue 2, 2015, Pages

  Rahmani, Rana ^a   Zarrini, Gholamreza ^a   Sheikhzadeh, Farzam ^a   Aghamohammadzadeh, Naser ^b  

^a UNIVERSITY OF TABRIZ   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic resistant; Bacteriophage; Hospital; Mice

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CIPROFLOXACIN; COLISTIN; DOXYCYCLINE; GENTAMICIN; KANAMYCIN; NALIDIXIC ACID; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM COLONY; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS REACTION; DECUBITUS; DIABETES MELLITUS; DRUG EFFECT; ESCHERICHIA COLI; FOOT ULCER; HOST RANGE; HUMAN; MOUSE; NONHUMAN;

EID: 84976316348     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: 10.5812/jjm.17744     Document Type: Article

References (15)

1. Sulakvelidze A. The challenges of bacteriophage therapy. Eur Ind Pharm. 2011; 10: 14-8.
2. Abhilash M, Vidya A, Jagadevi T. Bacteriophage therapy: A war against antibiotic resistant bacteria. Internet J Altern Med. 2009; 7 (1),e 13668.
3. Ghannad MS, Mohammadi A. Bacteriophage: time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran J Basic Med Sci. 2012; 15 (2): 693.
4. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18 (6): 237-8.
5. Alexander SK, Strete D, Niles MJ. Laboratory exercises in organismal and molecular microbiology.: McGraw-Hill; 2004.
6. Pattee PA. Use of tetrazolium for improved resolution of bacteriophage plaques. J Bacteriol. 1966; 92 (3): 787-8.
7. Momoh ARM, Orhue PO, Idonije OB, Oaikhena AG, Nwoke EO, Momoh AA. The antibiogram types of Escherichia coli isolated from suspected urinary tract infection samples. J Microbiol Biotech Res. 2011; 1 (3): 57-65.
8. Mubita C, Syakalima M, Chisenga C, Munyeme M, Bwalya M, Chifumpa G, et al. Antibiograms of faecal Escherichia coli and Enterococci species isolated from pastoralist cattle in the interface areas of the Kafue basin in Zambia. Vet Arh. 2008; 78 (2): 179.
9. Thaker H, Brahmbhatt M, Nayak J. Study on occurrence and antibiogram pattern of Escherichia coli from raw milk samples in Anand, Gujarat, India. Vet World. 2012; 5 (9): 556.
10. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol. 1982; 128 (2): 307-18.
11. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol. 1987; 133 (5): 1111-26.
12. Barrow P, Lovell M, Berchieri A Jr. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol. 1998; 5 (3): 294-8.
13. Jamalludeen N, Johnson RP, Shewen PE, Gyles CL. Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet Microbiol. 2009; 136 (1-2): 135-41.
14. Gu J, Liu X, Li Y, Han W, Lei L, Yang Y, et al. A method for generation phage cocktail with great therapeutic potential. PLoS One. 2012; 7 (3).
15. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005; 49 (7): 2874-8.